Literature DB >> 25815848

Metabolism and its sequelae in cancer evolution and therapy.

Robert J Gillies1, Robert A Gatenby.   

Abstract

Cancers progress through a series of events that can be characterized as "somatic evolution." A central premise of Darwinian evolutionary theory is that the environment imparts pressure to select for species that are most fit within that particular microenvironmental context. Furthermore, the rate of evolution is proportional to both (1) the strength of the environmental selection and (2) the phenotypic variance of the selected population. It is notable that, during the progression of cancers from carcinogenesis to local invasion to metastasis, the selective landscape continuously changes, and throughout this process, there is increased selection for cells that have altered metabolic phenotypes: implying that these phenotypes impart a selective advantage during the process of environmental selection. One of the most prevalent selected phenotypes is that of aerobic glycolysis, that is, the continued fermentation of glucose even in the presence of adequate oxygen. The mechanisms of this so-called "Warburg effect" have been well studied, and there are multiple models to explain how this occurs at the molecular level. Herein, we propose that unifying insights can be gained by evaluating the environmental context within which this phenotype arises. In other words, we focus not on the "how" but the "why" do cancer cells exhibit high aerobic glycolysis. This is best approached by examining the sequelae of aerobic glycolysis that may impart a selective advantage. Many of these have been considered, including generation of anabolic substrates, response rates of glycolysis vis-à-vis respiration, and generation of antioxidants. A further sequeala considered here is that aerobic glycolysis results in a high rate of lactic acid production; resulting in acidification of the extracellular space. Indeed, it has been shown that a low extracellular pH promotes local invasion, promotes metastasis, and inhibits antitumor immunity. In naturally occurring cancers, low extracellular pH is a strong negative prognostic indicator of metastasis-free survival. Furthermore, it has been shown that inhibition of extracellular acidosis can inhibit metastasis and promote antitumor immunity. Hence, we propose that excess acid production confers a selective advantage for cells during the somatic evolution of cancers.

Entities:  

Mesh:

Year:  2015        PMID: 25815848      PMCID: PMC4446699          DOI: 10.1097/PPO.0000000000000102

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  71 in total

Review 1.  Causes and consequences of tumour acidity and implications for treatment.

Authors:  M Stubbs; P M McSheehy; J R Griffiths; C L Bashford
Journal:  Mol Med Today       Date:  2000-01

2.  Acid treatment of melanoma cells selects for invasive phenotypes.

Authors:  Raymond E Moellering; Kvar C Black; Chetan Krishnamurty; Brenda K Baggett; Phillip Stafford; Matthew Rain; Robert A Gatenby; Robert J Gillies
Journal:  Clin Exp Metastasis       Date:  2008-02-27       Impact factor: 5.150

3.  Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells.

Authors:  Joshua J Steffan; Jared L Snider; Omar Skalli; Tomas Welbourne; James A Cardelli
Journal:  Traffic       Date:  2009-06       Impact factor: 6.215

Review 4.  Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential.

Authors:  Amy S Lee
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

5.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

6.  Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors:  Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

Review 7.  Hypoxia and adaptive landscapes in the evolution of carcinogenesis.

Authors:  Robert J Gillies; Robert A Gatenby
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

Review 8.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

9.  Regulation of anoikis by deleted in breast cancer-1 (DBC1) through NF-κB.

Authors:  Sun Hee Park; Philip Riley; Steven M Frisch
Journal:  Apoptosis       Date:  2013-08       Impact factor: 4.677

Review 10.  The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.

Authors:  D Craig Allred; Powel Brown; Daniel Medina
Journal:  Breast Cancer Res       Date:  2004-09-22       Impact factor: 6.466

View more
  36 in total

1.  HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI.

Authors:  Marina Radoul; Chloé Najac; Pavithra Viswanath; Joydeep Mukherjee; Mark Kelly; Anne Marie Gillespie; Myriam M Chaumeil; Pia Eriksson; Romelyn Delos Santos; Russell O Pieper; Sabrina M Ronen
Journal:  NMR Biomed       Date:  2018-12-18       Impact factor: 4.044

Review 2.  Carbonic anhydrases as disease markers.

Authors:  Sabina Zamanova; Ahmed M Shabana; Utpal K Mondal; Marc A Ilies
Journal:  Expert Opin Ther Pat       Date:  2019-06-17       Impact factor: 6.674

Review 3.  The Warburg Effect and Mass Spectrometry-based Proteomic Analysis.

Authors:  Weidong Zhou; Lance A Liotta; Emanuel F Petricoin
Journal:  Cancer Genomics Proteomics       Date:  2017 Jul-Aug       Impact factor: 4.069

Review 4.  Emerging applications of metabolomics in drug discovery and precision medicine.

Authors:  David S Wishart
Journal:  Nat Rev Drug Discov       Date:  2016-03-11       Impact factor: 84.694

Review 5.  Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Authors:  Mahmoud Chaker; Audrey Minden; Suzie Chen; Robert H Weiss; Eduardo N Chini; Amit Mahipal; Asfar S Azmi
Journal:  Expert Opin Ther Targets       Date:  2017-12-10       Impact factor: 6.902

6.  Spatial Measures of Genetic Heterogeneity During Carcinogenesis.

Authors:  K Storey; M D Ryser; K Leder; J Foo
Journal:  Bull Math Biol       Date:  2016-11-30       Impact factor: 1.758

7.  pH-Sensitive Multiligand Gold Nanoplatform Targeting Carbonic Anhydrase IX Enhances the Delivery of Doxorubicin to Hypoxic Tumor Spheroids and Overcomes the Hypoxia-Induced Chemoresistance.

Authors:  Ahmed M Shabana; Utpal K Mondal; Md Raqibul Alam; Taylor Spoon; Codee Alicia Ross; Muniswamy Madesh; Claudiu T Supuran; Marc A Ilies
Journal:  ACS Appl Mater Interfaces       Date:  2018-05-15       Impact factor: 9.229

8.  Hypoxia-activated cytotoxicity of benznidazole against clonogenic tumor cells.

Authors:  Quhuan Li; Qun Lin; Zhong Yun
Journal:  Cancer Biol Ther       Date:  2016-10-27       Impact factor: 4.742

Review 9.  UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research.

Authors:  Ala F Nassar; Terence Wu; Samuel F Nassar; Adam V Wisnewski
Journal:  Drug Discov Today       Date:  2016-12-02       Impact factor: 7.851

10.  The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.

Authors:  Quhuan Li; Qun Lin; Hoon Kim; Zhong Yun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.